Signal transduction in MDS bone marrow populations
Introduction
Myelodysplastic syndromes (MDS) are a group of hematological neoplastic diseases heterogeneous for clinical presentation and genetic alterations. The characterization of biological properties of myelodysplastic cells in vitro is hampered by lack of animal models and by difficulties in isolating the cell populations responsible for the disease and/or its maintenance. Although high throughput techniques have recently identified many genetic lesions present in MDS, the majority of cases lack an easily detectable molecular or phenotypic marker. The burden of disease is routinely evaluated morphologically, by manually scoring dysplastic cells, and only recently have other methods been proposed, including flow cytometric analysis (1, 2) or molecular quantitation of oncogenes such as WT-1 (3, 4) . In fact, at present, three diagnostic and prognostic evaluation systems are used to classify MDS, the French-American-British (FAB) classification (5), the International Prognostic Score System (IPSS) (6) , and the World Health Classification (WHO) classification (7), along with the WHO classification-based prognostic scoring system, WPSS (8) . Both prognostic systems are dependent on the morphological detection of immature cells and on the presence of cytogenetic abnormalities.
Cells from the BM of MDS patients have altered signal transduction pathways. In particular, the erythropoietin (EPO) receptor is expressed at a normal density on MDS cells, but STAT5 activation in response to EPO stimulation is defective (9) . This observation was attributed to intracellular structural defects in the EPO receptors of MDS cells, but this was not specifically demonstrated (10, Signal transduction in MDS bone marrow populations On the other hand, one of the typical clinical manifestations of MDS, peripheral cytopenia with hyperproliferative BM and ineffective hemopoiesis, is caused by excessive premature apoptosis of hematopoietic precursors (15) .
In this study, the signal transduction pathways controlling proliferation and apoptosis in distinct subpopulations of MDS BM cells were evaluated to identify a possible dysplastic signature.
Differences in the basal activation of signaling pathways were evaluated among marrow cell subtypes and among MDS morphological subtypes, defined according to the WHO classification.
Signal transduction was also evaluated in response to erythropoietic and granulopoietic stimulating agents, broadly used in clinics for the treatment of low-risk IPSS MDS patients. In particular, STAT5 phosphorylation in response to EPO was examined with respect to clinical outcome in the MDS cases who were treated with EPO based on clinical parameters (IPSS LOW/INT-1; endogenous EPO < 500U/l; no transfusion need), which indicated them as potentially responsive to erythropoiesis-stimulating agents (ESAs).
Materials and methods

Patients
BM blood samples were obtained from 60 patients diagnosed with MDS at the Hematology Unit, AOU Careggi, University of Florence, Italy. Patient characteristics are reported in Table 1 . BM cells from six healthy donors were included in the study. Informed consent was obtained according to institutional guidelines. MDS diagnosis was made in accordance with the WHO criteria. Three CMML and two CMML-2 cases were diagnosed according to the morphologic and cytochemical criteria of the FAB classification and were included in the study. All analyses were performed at the time of diagnosis. BM cells were cultured and processed, and conventional cytogenetic analysis was performed on unstimulated BM cultures after 24 h by trypsin-Giemsa banding (GTG-banding).
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Statistical and cluster analysis
Differences in basal phosphorylation were compared by calculating the specific MFI as the ratio of the mean fluorescence intensity (MFI) for each sample divided by the MFI of the isotype control.
The MFI cutoff to consider activated phosphorylation (> 1.2) was established calculating the MFI median values +/-standard deviation of unstimulated normal controls.
A protein was considered strongly activated when the specific MFI was greater than 5.0, activated when the specific MFI was between 2.0 and 5.0, weakly activated when the specific MFI was between 1.2 and 2.0, and not activated when the specific MFI was less or equal to 1.2. Changes in the phosphorylation status of proteins following cytokine stimulation were determined by calculating the ratios of the specific MFIs of stimulated versus unstimulated cell populations.
The non-parametric Wilcoxon Kruskal-Wallis tests were used to evaluate statistical significance. P ≤0.05 was considered statistically significant. The response to EPO treatment in vivo was evaluated according to IWG criteria as an increase of 2 g/dl in Hb levels after 8 weeks of EPO treatment or transfusion independence for > 8 weeks (19) . The correlation between EPO responses in vivo and in vitro was calculated by the non-parametric Spearman's test. Analyses were conducted using the StataCorp2003 software program. To assess the validity of the in vitro results with respect to in vivo response to EPO, we estimated the sensitivity, the specificity and the positive and negative predictive values with their 95% confidence intervals. Analyses of flow cytometry data were performed using unsupervised algorithms that allow for samples with similar patterns of protein basal activation or similar cytokine responses in vitro to be grouped together. Heat maps and dendrograms were drawn using the open-source versions of the Cluster and TreeView programs*.
(*) http://bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/software.htm.
Research. Table 1 ). The pattern of activation is listed in Table   2 .
STAT5 was phosphorylated in the majority of MDS cases, but particularly in 5/54 cases (1 RA, 1 RCMD, 2 RAEB-1, and 1 RAEB-2). Caspase-3 was also strongly activated in 5/54 cases (1 RA, 1 RARS, 1 RCMD, 1 RAEB-1, and 1 RAEB-2). Healthy donor cells did not exhibit basal activation of any of the proteins studied (Supplemental Figure 1) .
Statistical analysis showed that STAT5 and caspase-3 were significantly activated in CD34+ MDS cells compared to normal donor cells (P = 0.001 and P = 0.002, respectively; Figure 1A ), and that STAT5 was significantly phosphorylated in the RA and RAEB-1 WHO subgroups as compared to healthy donors (P < 0.001 and P < 0.001).
A heterogeneous pattern of basal activation was observed by cluster analysis, in that MDS cases belonging to the same WHO classification subtype did not cluster together ( Figure 1B ). Flow cytometric analysis of ERK1/2, STAT5, p38 MAPK, and caspase-3 basal activation in one representative case (#18) is shown in Supplementary Figure 2 .
Spontaneous basal activation of ERK1/2, STAT5, p38 MAPK and caspase-3 in CD45+ cells
Basal activation of ERK1/2, p38 MAPK, STAT5 and caspase-3 was studied in CD45+ cells obtained from 45/60 MDS patients and six healthy donors (Supplemental Table 2 ). The pattern of activation is depicted in Table 2. ERK1/2 and p38 MAPK phosphorylation was a rare event in these cells. The intensity of phosphorylation of STAT5 and caspase-3 was heterogenous but weak in the majority of cases (1. Signal transduction in MDS bone marrow populations < MFI < 2). BM cells from the normal donors did not show any basal activation of the studied proteins (Supplemental Figure 3) . Statistical analysis showed that STAT5 and caspase-3 were significantly activated in CD45+ MDS cells compared with healthy donors controls (P < 0.001 and P = 0.003, respectively; Figure 1C ) and that STAT5 was significantly phosphorylated in patients with the RA and RAEB-1 subtypes (P < 0.001 and P = 0.001, respectively) compared to normal cases.
Cluster analysis showed a heterogenous pattern of activation, and the cases belonging to the same WHO subtypes did not cluster together, although normal cases did ( Figure 1D ).
Spontaneous basal activation of ERK1/2, STAT5, p38 MAPK, and caspase-3 in CD71+CD45-cells
Basal activation of ERK1/2, STAT5, p38 MAPK, and caspase-3 was studied in BM from 45/60 MDS patients and six normal donors. Two of the MDS cases analyzed did not contain CD71+CD45-cells. The activation of signaling pathways in this subpopulation was low overall and is shown in Table 2 .
Healthy donor cells and MDS cases did not present basal activation of ERK1/2, p38 MAPK, or caspase-3 (Supplemental Figure 4) . STAT5 was the only protein significantly activated in the CD71+CD45-subpopulation compared with normal cells (P = 0.006; Figure 1E ). Cases of RA and RAEB-1 (P = 0.001 and P = 0.001, respectively) showed the highest levels of STAT5 activation in absence of any stimuli. Five RA cases with the highest STAT5 activation (MFI > 3) also grouped together by cluster analysis ( Figure 1F ).
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In parallel, ERK1/2 and STAT5 activation was also studied in normal BMMC after EPO treatment for 5, 15, 30, and 60 min or TPA treatment for 10 min. Signal transduction in MDS bone marrow populations Three main groupings were visible upon cluster analysis. Cluster 1 included the six healthy donors, one RCMD case and one CMML-2 case. Cluster 2 contained 11 MDS responding to EPO and belonging to various WHO subtypes; STAT5 activation in these cases was lower than in healthy donors. Cluster 3 included MDS cases not responding to EPO ( Figure 3B ). Subsequently, the in vivo response to EPO was evaluated in 22 non-transfused MDS patients. These patients were considered to have a high probability of response to EPO according to accepted clinical criteria, in that all 22 were transfusion-independent, with endogenous serum EPO levels < 500U/L, and 17/22 
Discussion
MDS are a complex group of diseases. Very few studies have focused on dissecting the signaling pathways in MDS cells (13, 21) . This study evaluated the spontaneous basal activation of ERK1/2, p38 MAPK, STAT5, and caspase-3 in 60 primary human MDS cases, and the modulation of this activation by EPO and G-CSF using a flow cytometric method which allowed quantitation of phosphorylation in the distinct CD45+, CD34+, and CD71+CD45-BMMC subpopulations
The spontaneous activation of ERK1/2, p38 MAPK, STAT5, and caspase-3 differed markedly between normal and MDS cells and was highly heterogeneous among MDS cases and also among the different MDS cell subpopulations studied. This is due to the fact that, in MDS marrow, progenitors with different stages of differentation and different genotypes are present. Our aim was not to study a selected supopulation, as done in gene expression profiling studies, but to examine the difference in pathways among these supopulations.
The intensity of activation of STAT5, caspase-3, and p38, and the number of cases in which activation was observed, was highest in CD34+ cells, suggesting that this is the most "active" subpopulation in MDS. This enhanced signaling could contribute to the progressive depletion of early hematopoietic cells seen in MDS patients due to defective self-renewal, differentiation and quiescence (22) . In addition, STAT5 and ERK1/2 activation in response to EPO was defective in CD71+CD45-MDS marrow cells. A defect in STAT5 gene expression characterizes lenalidomide responsiveness irrespective of the presence of the 5q deletion and is an essential pre-requisite for lenalidomide sensitivity (27) . As already shown by other authors, STAT5 activation in response to in vitro EPO was absent or significantly reduced in all MDS cases compared to normal controls. No significant differences in the presence of EPO-R, nor in the burden of the MDS clone, as indicated by abnormal metaphases (data not shown), were detected between responders and non-responders.
This abnormality seems to allow a clear distinction between normal and MDS CD71+CD45-progenitors. These data are consistent with recent reports (21) . This intrinsic defect in erythroid development is characteristic of the disease and mainly functionally affects CD71+CD45-cells (9, 27) . Even when all metaphases scored are abnormal, the response to EPO may be present and thus attributed to the MDS clone (case #25; see results).
In vitro response to EPO, measured by cytofluorimetry in CD71+CD45-cells, correlated strictly with the in vivo response. This method could thus be used as a test that could accurately predict clinically responsive patients, even among those presenting with favorable biological/clinical parameters such as endogenous EPO levels < 500u/L, low marrow blasts, and tranfusion independency. This analysis particularly focused on such MDS cases. These characteristics identify the group of MDS cases with the lowest Nordic score (28) , and who therefore are predicted to have the highest probability of response to EPO (plus G-CSF) treatment, as confirmed in a recent metaanalysis (29) . Within this subset of possibly responsive patients, the cytofluorimetric test described here strongly predicted the clinically non-responsive patients. Recently, an aberrant phenotype of Signal transduction in MDS bone marrow populations insensitive in the STAT5 phosphorylation test, confirming the correlation between EPO insensitivity and CD34 immunophenotype. An inconsistency of the two types of evaluation was observed only in one isolated case. Therefore, the test described in this report has a very high predictive power for the in vivo EPO response, particularly as it is independent of the presence of CD34+ cells. A correlation between the flow score of BM cells and the IPSS score has been shown in MDS (30) . In that study, and in follow-up studies by the same group, the predictability of the response to treatments like HSCT and immunosuppressive drugs was evaluated (31, 32) . 
Signal transduction in MDS bone marrow populations counterparts (35) . In addition, this data could in fact support a safe, and consequently broader, use of G-CSF in the treatment of MDS.
This study provides the first evidence that is possible to identify a dysplastic phosphorylation signature, opening novel possibilities for investigation of the heterogeneous pathophysiology of MDS. This data also demonstrates that the EPO clinical response may be predicted with a rapid cytofluorimetric test that is more accurate than previously applied biological/clinical parameters.
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